Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TK1 | P04183 | 1/20 | 0.31 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18080565 | 0.84 | ALDH1A1 (0.32) | ALDH1A1KDM4E | |
| SCHEMBL16631767 | 0.81 | MAPK1 (0.34) | ALDH1A1KDM4EMAPK1RAB9AHPGD | |
| SCHEMBL16631919 | 0.78 | CRBN (0.34) | RAB9A | |
| SCHEMBL18081793 | 0.76 | KDM4E (0.35) | ALDH1A1KDM4ERAB9AHPGD | |
| SCHEMBL16631752 | 0.73 | KDM4E (0.33) | ALDH1A1KDM4E | |
| SCHEMBL18081777 | 0.73 | KDM4E (0.33) | ALDH1A1KDM4E | |
| SCHEMBL16631762 | 0.69 | HPGD (0.36) | RAB9AHPGDMAPT | |
| SCHEMBL16631914 | 0.67 | ALDH1A1 (0.34) | ALDH1A1KDM4ERAB9AHPGD | |
| SCHEMBL25105413 | 0.64 | TDP1 (0.39) | ALDH1A1MAPK1RAB9AHPGD | |
| SCHEMBL28369861 | 0.63 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPK1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | ALDH1A1 4189/4885KDM4E 4689/4885MAPK1 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.